Please Wait...

HA // Hyaluronic Acid

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Hyaluronic acid (HA) is also known as hyaluronate or hyaluronan. This macromolecule is a ubiquitous linear polymer, especially abundant in connective tissues. HA is synthetized in the plasma membrane by a membrane-bound protein by addition of sugar units (D-glucuronic acid and D-N-acetylglucosamine, linked via alternating β-1,4 and β-1,3 glycosidic bonds) from a nucleotide precursor and followed by translocation to the extracellular space (Fraser et al., 1997). HA found in low concentration in blood comes from the peripheral tissues through the lymph and in physiological condition is rapidly took up and degraded by the liver. In patients with liver diseases, such as liver cirrhosis, increased serum levels of HA have been found. Increased blood levels can also be the result of inflammatory condition such as rheumatoid arthritis, psoriasis and scleroderma (Laurent and Fraser, 1992).

Bioclinica Lab employs a sandwich protein binding manual assay, which use Hyaluronic Acid Binding Protein for the capture and detection of HA. This assay is designed for the measurement of Collagen IV in serum.


Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

We're hiring recent tech grads in #RTP for #pharma sector! Our innov. clinical financial solution gives our client…
bioclinica (3 hours ago)
Great to be @DrugInfoAssn DIA China! Ask us @bioclinica how sponsors & CROs can optimize electronic data capture…
bioclinica (9 hours ago)
RT @bioclinica: Kinks in the clinical supply chain? Check out how one of our clients is using clinical supply optimization technology for m…
bioclinica (9 hours ago)
RT @bioclinica: Welcoming everyone to KOP for #OCTEast Coast!!
bioclinica (9 hours ago)
Welcoming everyone to KOP for #OCTEast Coast!!
bioclinica (Yesterday)
Case processing is an important aspect of post-marketing drug safety surveillance. Here's a case study showing how…
bioclinica (2 days ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen